Literature DB >> 8420491

Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid.

J C Guillaume1, L Vaillant, P Bernard, C Picard, C Prost, B Labeille, B Guillot, C Foldès-Pauwels, F Prigent, P Joly.   

Abstract

BACKGROUND AND
DESIGN: Bullous pemphigoid is usually treated with systemic corticosteroids. Side effects are common in elderly patients, justifying the search for adjuvant therapy. This randomized, multicentric unblind study was designed to assess the efficacy of azathioprine or plasma exchange when added to conventional doses of prednisolone. One hundred patients with active disease entered the study. They were randomly allocated to receive 28 days of treatment with oral prednisolone sodium metasulfobenzoate (1 mg/kg per day) either alone or in combination with oral azathioprine (100 to 150 mg/d) or four large-volume plasma exchanges. After 28 days, the prednisolone doses were progressively decreased according to the same strict regimen in the three groups (in combination with oral azathioprine in group 2).
RESULTS: The clinical results were evaluable in 98 of the 100 patients included in the study. There was no appreciable difference in the percentages of complete remission of the disease in the three therapeutic groups at 28 days (71%, 80%, and 71%, respectively) or at 6 months (42%, 39%, and 29%, respectively). Severe complications were more often observed among patients receiving azathioprine. At 6 months, 14 of 98 patients had died, without any differences noted among the three study groups.
CONCLUSIONS: We conclude that neither azathioprine nor plasma exchange is effective enough to be used routinely as an adjuvant to corticosteroids in the management of bullous pemphigoid.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420491

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  17 in total

Review 1.  Interventions for bullous pemphigoid.

Authors:  Gudula Kirtschig; Philippa Middleton; Cathy Bennett; Dedee F Murrell; Fenella Wojnarowska; Nonhlanhla P Khumalo
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  The role of topical corticosteroids in bullous pemphigoid in the elderly.

Authors:  Pascal Joly; Juliette Fontaine; Jean-Claude Roujeau
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

Review 5.  Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature.

Authors:  Brian Chang; Ashok Tholpady; Richard S P Huang; Elena Nedelcu; Yu Bai
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 6.  Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics.

Authors:  A Anstey
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

7.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

8.  Randomized controlled trials needed for bullous pemphigoid interventions.

Authors:  Maria Teresa García-Romero; Victoria P Werth
Journal:  Arch Dermatol       Date:  2012-02

Review 9.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Management of autoimmune skin disorders in the elderly.

Authors:  Wei Jing Loo; Nigel P Burrows
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.